FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023679944> ?p ?o ?g. }

• W2023679944 endingPage "260" @default.
• W2023679944 startingPage "252" @default.
• W2023679944 abstract "Therapeutic options for men with metastatic prostate cancer are expanding. Here we discuss the scientific progress in this disease that led to approval of several agents in the last decade and highlight ongoing clinical investigation.In androgen-sensitive disease, trials are evaluating the role of intermittent androgen-deprivation therapy, early chemotherapy, and novel targeted and hormonal therapies. For chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC), abiraterone is effective. Trials with additional agents targeting androgen receptor (AR) signaling, such as TAK-700 and enzalutamide, are ongoing. Other agents in development target the endothelin pathway, angiogenesis, AR chaperones, and immune mechanisms. Docetaxel with prednisone remains the standard first-line chemotherapeutic regimen as trials incorporating novel agents with docetaxel have been negative. Postdocetaxel, enzalutamide improves survival. Early results with cabozantinib are encouraging, and phase III studies are ongoing. Denosumab and radium-223 reduce the risk of skeletal-related events (SREs), but only radium-223 improves survival.Progress in understanding the disease biology and mechanisms of castration resistance led to significant therapeutic advancements, particularly in the setting of mCRPC in which several phase III trials, each incorporating agents with different mechanisms of action, have improved survival. As a result, new options exist, and the standard of care has changed significantly. Further advances are anticipated." @default.
• W2023679944 created "2016-06-24" @default.
• W2023679944 creator A5041126882 @default.
• W2023679944 creator A5060006096 @default.
• W2023679944 date "2013-05-01" @default.
• W2023679944 modified "2023-09-25" @default.
• W2023679944 title "Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer" @default.
• W2023679944 cites W1963635251 @default.
• W2023679944 cites W2014132187 @default.
• W2023679944 cites W2024548912 @default.
• W2023679944 cites W2034000571 @default.
• W2023679944 cites W2042692879 @default.
• W2023679944 cites W2062894135 @default.
• W2023679944 cites W2066086539 @default.
• W2023679944 cites W2069640477 @default.
• W2023679944 cites W2074886278 @default.
• W2023679944 cites W2080439368 @default.
• W2023679944 cites W2081463541 @default.
• W2023679944 cites W2090685497 @default.
• W2023679944 cites W2103959341 @default.
• W2023679944 cites W2110534364 @default.
• W2023679944 cites W2117089606 @default.
• W2023679944 cites W2120292596 @default.
• W2023679944 cites W2123526148 @default.
• W2023679944 cites W2130088545 @default.
• W2023679944 cites W2130803372 @default.
• W2023679944 cites W2135078918 @default.
• W2023679944 cites W2137467802 @default.
• W2023679944 cites W2139860898 @default.
• W2023679944 cites W2148643283 @default.
• W2023679944 cites W2151063703 @default.
• W2023679944 cites W2153935963 @default.
• W2023679944 cites W2155846302 @default.
• W2023679944 cites W2156451504 @default.
• W2023679944 cites W2159445058 @default.
• W2023679944 cites W2165088640 @default.
• W2023679944 cites W2165782799 @default.
• W2023679944 cites W2999598241 @default.
• W2023679944 cites W3000363219 @default.
• W2023679944 cites W3000564989 @default.
• W2023679944 cites W3003234309 @default.
• W2023679944 cites W3009012041 @default.
• W2023679944 doi "https://doi.org/10.1097/cco.0b013e32835ff161" @default.
• W2023679944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23511665" @default.
• W2023679944 hasPublicationYear "2013" @default.
• W2023679944 type Work @default.
• W2023679944 sameAs 2023679944 @default.
• W2023679944 citedByCount "33" @default.
• W2023679944 countsByYear W20236799442013 @default.
• W2023679944 countsByYear W20236799442014 @default.
• W2023679944 countsByYear W20236799442015 @default.
• W2023679944 countsByYear W20236799442016 @default.
• W2023679944 countsByYear W20236799442017 @default.
• W2023679944 countsByYear W20236799442018 @default.
• W2023679944 countsByYear W20236799442019 @default.
• W2023679944 countsByYear W20236799442020 @default.
• W2023679944 crossrefType "journal-article" @default.
• W2023679944 hasAuthorship W2023679944A5041126882 @default.
• W2023679944 hasAuthorship W2023679944A5060006096 @default.
• W2023679944 hasConcept C121608353 @default.
• W2023679944 hasConcept C126322002 @default.
• W2023679944 hasConcept C143998085 @default.
• W2023679944 hasConcept C2775832370 @default.
• W2023679944 hasConcept C2776551883 @default.
• W2023679944 hasConcept C2777899217 @default.
• W2023679944 hasConcept C2778971682 @default.
• W2023679944 hasConcept C2780192828 @default.
• W2023679944 hasConcept C2781064419 @default.
• W2023679944 hasConcept C2781190966 @default.
• W2023679944 hasConcept C535046627 @default.
• W2023679944 hasConcept C61367390 @default.
• W2023679944 hasConcept C71924100 @default.
• W2023679944 hasConceptScore W2023679944C121608353 @default.
• W2023679944 hasConceptScore W2023679944C126322002 @default.
• W2023679944 hasConceptScore W2023679944C143998085 @default.
• W2023679944 hasConceptScore W2023679944C2775832370 @default.
• W2023679944 hasConceptScore W2023679944C2776551883 @default.
• W2023679944 hasConceptScore W2023679944C2777899217 @default.
• W2023679944 hasConceptScore W2023679944C2778971682 @default.
• W2023679944 hasConceptScore W2023679944C2780192828 @default.
• W2023679944 hasConceptScore W2023679944C2781064419 @default.
• W2023679944 hasConceptScore W2023679944C2781190966 @default.
• W2023679944 hasConceptScore W2023679944C535046627 @default.
• W2023679944 hasConceptScore W2023679944C61367390 @default.
• W2023679944 hasConceptScore W2023679944C71924100 @default.
• W2023679944 hasIssue "3" @default.
• W2023679944 hasLocation W20236799441 @default.
• W2023679944 hasLocation W20236799442 @default.
• W2023679944 hasOpenAccess W2023679944 @default.
• W2023679944 hasPrimaryLocation W20236799441 @default.
• W2023679944 hasRelatedWork W122177069 @default.
• W2023679944 hasRelatedWork W2135620818 @default.
• W2023679944 hasRelatedWork W2158933186 @default.
• W2023679944 hasRelatedWork W2274307715 @default.
• W2023679944 hasRelatedWork W2568045406 @default.
• W2023679944 hasRelatedWork W2590124563 @default.
• W2023679944 hasRelatedWork W2770702948 @default.
• W2023679944 hasRelatedWork W3023947295 @default.

• next